ADC ČIŽMÁRIKOVÁ, Martina [50 %] - TAKÁČ, Peter [25 %] - SPENGLER, Gabriela [10 %] - KINCSES, Annamária [5 %] - NOVÉ, Márta [2 %] - VILKOVÁ, Mária [3 %] - MOJŽIŠ, Ján [5 %]. New Chalcone derivative inhibits ABCB1 in multidrug resistant T-cell lymphoma and colon adenocarcinoma cells. In Anticancer Research. ISSN 0250-7005, 2019, vol. 39, no. 12, p. 6499-6505. (2019: 1.994 - IF, 1.931 - IF 5y, 117 - H-index, 0.716 - SJR, Q2 - SJR Best Q, Q4 - JCR Best Q). (2019

ADC ČIŽMÁRIKOVÁ, Martina [50 %] - TAKÁČ, Peter [25 %] - SPENGLER, Gabriela [10 %] - KINCSES, Annamária [5 %] - NOVÉ, Márta [2 %] - VILKOVÁ, Mária [3 %] - MOJŽIŠ, Ján [5 %]. New Chalcone derivative inhibits ABCB1 in multidrug resistant T-cell lymphoma and colon adenocarcinoma cells. In Anticancer Research. ISSN 0250-7005, 2019, vol. 39, no. 12, p. 6499-6505. (2019: 1.994 - IF, 1.931 - IF 5y, 117 - H-index, 0.716 - SJR, Q2 - SJR Best Q, Q4 - JCR Best Q). (2019 - Current Contents).

Basic data
OCA1. Surname awarded to the assessed person	Takáč
OCA2. Name awarded to the assessed person	Peter
OCA3. Degrees awarded to the assessed person	Assoc. prof. , Pharm.D., PhD
OCA4. Hyperlink to the entry of the person in the Register of university staff	https://www.portalvs.sk/regzam/detail/27235
OCA5. Area of assessment	study programme pharmacy · I. + II. degree
OCA6. Category of the research/artistic/other output	scientific output
OCA7. Year of publication of the research/artistic/other output	2019
OCA8. ID of the record in the Central Registry of Publication Activity (CRPA) or the Central Registry of Artistic Activity (CRAA)	ID: 179457
OCA9. Hyperlink to the record in CRPA or CRAA	https://app.crepc.sk/?fn=detailBiblioForm&sid=74EB4C9215C2376F54B226C93D
Characteristics of the output that is not registered in CRPA or CRAA
OCA10. Hyperlink to the record in another publicly accessible register, catalogue of research/ artistic/other outputs
OCA11. Characteristics of the output in the format of the CRPA or the CRAA bibliographic record, if the output is not available in a publicly accessible register or catalogue of outputs	ADC ČIŽMÁRIKOVÁ, Martina [50 %] - TAKÁČ, Peter [25 %] - SPENGLER, Gabriela [10 %] - KINCSES, Annamária [5 %] - NOVÉ, Márta [2 %] - VILKOVÁ, Mária [3 %] - MOJŽIŠ, Ján [5 %]. New Chalcone derivative inhibits ABCB1 in multidrug resistant T-cell lymphoma and colon adenocarcinoma cells. In Anticancer Research. ISSN 0250-7005, 2019, vol. 39, no. 12, p. 6499-6505. (2019: 1.994 - IF, 1.931 - IF 5y, 117 - H-index, 0.716 - SJR, Q2 - SJR Best Q, Q4 - JCR Best Q). (2019 - Current Contents).
OCA12. Type of the output (if the output is not registered in CRPA or CRAA)
OCA13. Hyperlink to the webpage where the output is available (full text, other documentation, etc.)
OCA14. Characteristics of the author's contribution
OCA15. Annotation of the output with contextual information concerning the description of creative process and the content of the research/artistic/other activity, etc.
Other data
OCA16. Annotation of the output in English	Development of new potential drugs to overcome multidrug resistance to chemotherapy is a big challenge for cancer treatment. Attention is also given to the natural compounds and their derivatives. The study aimed at evaluating the impact of a new chalcone derivative (1C) on multidrug resistant cell lines, focusing on P-glycoprotein (P-gp, ABCB1) inhibition, as well as 1C-doxorubicin interaction in vitro. Our results confirmed antiproliferative, cytotoxic, as well as ABCB1 inhibitory potential of 1C in both tested ABCB1-expressing cancer cell lines. Furthermore, 1C displayed synergistic interaction with doxorubicin. Our results suggest the 1C chalcone derivative as a promising compound against resistant lymphoma and colon cancer, which could be used in monotherapy or in combination with other chemotherapeutics.
OCA17. List of maximum 5 most significant citations corresponding to the output	[1]/[1] WALYELDEEN, Amr Ahmed - SABET, Salwa - EL-SHORBAGY, Haidan M. - ABDELHAMID, Ismail A. - IBRAHIM, Sherif Abdelaziz. Chalcones: Promising therapeutic agents targeting key players and signaling pathways regulating the hallmarks of cancer. In Chemico-Biological Interactions, 2023-01-05, 369, pp. ISSN 00092797. Dostupné na: https://doi.org/10.1016/j.cbi.2022.110297., Registrované v: SCOPUS [1]/[1] GHOBADI, Niloofar - KHALILI-TANHA, Ghazaleh - MEHRAMIZ, Mehrane - MAFTOOH, Mina - BANI, Nastaran - SHAHIDSALES, Soodabeh - KHAZAEI, Majid - AHMADI-SIMAB, Saeideh - RAHBARIAN, Raheleh - RAMSHINI, Hassan - FERNS, Gordon A. - GHARIB, Masoumeh - AVAN, Amir. Association of the 1236C>T variant of the multidrug resistance 1 gene with esophageal squamous cell carcinoma development and prognosis. In Human Gene, 2023-02-01, 35, pp. ISSN 27730441. Dostupné na: https://doi.org/10.1016/j.humgen.2022.201137., Registrované v: SCOPUS [1]/[1] KUSHWAHA, Ambuj Kumar - KAMAL, Arsala - SINGH, Himanshu Kumar - MAURY, Suresh Kumar - MONDAL, Tusar - SINGH, Sundaram. Photoinduced, Metal-Free Hydroacylation of Aromatic Alkynes for Synthesis of α,β-Unsaturated Ketones via C(spsup3/sup)-H Functionalization. In Organic Letters, 2024-02-23, 26, 7, pp. 1416-1420. ISSN 15237060. Dostupné na: https://doi.org/10.1021/acs.orglett.4c00031., Registrované v: SCOPUS [1]/[1] NOVIANY, Noviany - OSMAN, Hasnah - MOHAMAD, Suriyati - HADI, Sutopo - SATRIA, Heri - BUHANI, Buhani. Synthesis of some chalcones derivatives series and their antituberculosis activity. In Pure and Applied Chemistry, 2024-03-01, 96, 3, pp. 351-368. ISSN 00334545. Dostupné na: https://doi.org/10.1515/pac-2023-1127., Registrované v: SCOPUS [1]/[1] SWATI - RAZA, Asif - CHOWDHARY, Shefali - ANAND, Amit - SHAVETA - SHARMA, Arun K. - KUMAR, Kewal - KUMAR, Vipan. Rational Design and Synthesis of Isatin-Chalcone Hybrids Integrated with 1H-1,2,3-Triazole: Anti-Proliferative Profiling and Molecular Docking Insights. In ChemMedChem, 2024-07-15, 19, 14, pp. ISSN 18607179. Dostupné na: https://doi.org/10.1002/cmdc.202400015., Registrované v: SCOPUS
OCA18. Characteristics of the output's impact on socio-economic practice	The output brings a significant contribution to socio-economic practice in the field of cancer treatment, particularly in overcoming multidrug resistance, which is one of the biggest obstacles to effective chemotherapy. The discovery of a new chalcone derivative (1C) capable of inhibiting P-glycoprotein (ABCB1) and enhancing the effect of doxorubicin opens new possibilities for treating resistant forms of lymphoma and colorectal cancer. This increases the chances of more successful therapy for patients with tumor resistance, potentially improving quality of life and survival rates. At the same time, implementing this derivative in clinical practice may reduce costs associated with long-term treatment and hospitalization, contributing to more efficient use of healthcare resources. This research thus supports the development of innovative and affordable therapeutic approaches with significant socio-economic impact.
OCA19. Characteristics of the output and related activities' impact on the educational process	The output and related activities significantly enrich the educational process in the fields of pharmaceutical research and oncology. Presenting new findings about the chalcone derivative (1C) and its ability to overcome multidrug resistance enables students to better understand the complex mechanisms of drug resistance and synergistic drug effects. This research fosters the development of critical thinking, analytical skills, and an interdisciplinary approach combining chemistry, molecular biology, and medicine. Involving students in experimental projects on similar topics enhances their practical skills and motivation for research. Additionally, it familiarizes them with current trends and challenges in cancer treatment, contributing to the preparation of future professionals capable of innovating and improving healthcare.